ArticleInternational journal of clinical and experimental medicine2015
Therapeutic effects of cytoprotective agent on breast reconstruction after breast cancer surgery.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients will choose breast reconstruction after breast cancer surgery, while radiotherapy will damage skin and soft tissue so that will have adverse effect on reconstruction. In this study, we assume that the usage of Amifostine can reduce the incidence of complications after breast reconstruction so that provides more choices of reconstruction operation. Dividing SD rats into surgical placement expansion material group (include 15 ml normal saline) and simple operation group. Then further divide the former into non intervention group , radiation group and Radiation therapy combined with Amie amifostine treatment group. The decubation is 45 days after operation. Macroscopic evaluate the complications of skin and soft tissue by ImageJ. There is no obvious complications of skin and soft tissue for control group, radiotherapy alone group and radiotherapy with application of Amifostine group by macroscopic evaluation. The animals that are in expanded object group, damage probability of skin and soft tissue when use Amifostine is lower than that of radiotherapy alone group (30% vs. 69%, P=0.041). ImageJ shows the necrosis probability of skin and soft tissue when use Amifostine is obvious lower than radiotherapy alone group (6.96% vs. 12.94%, P=0.019). In conclusion, prevention and treatment of Amifostine can significantly reduce the complications of skin and soft tissue which is helpful to breast reconstruction after breast cancer surgery.
Indexed as
Identifiers
26885163PMC4724009W2275745337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.